ASCO Annual Meeting News of the Day: Sunday, June 2, 2019

Jun 02, 2019

The 2019 ASCO Annual Meeting, taking place May 31 through June 4 in Chicago, brings together more than 40,000 oncology professionals from around the world to present and discuss the latest research in cancer treatment and patient care.

Explore today's late-breaking abstracts below, and read today’s patient-friendly news roundup on Cancer.Net, ASCO’s patient information website.

Earlier Ovarian Cancer Diagnoses and Treatment Seen After ACA Implementation LBA5563
An analysis of data from the National Cancer Database found that after implementation of the 2010 Affordable Care Act (ACA), ovarian cancer was diagnosed and treated at an earlier stage among women under age 65. Learn More 

Private Insurance, Higher Regional Incomes, and Certain Practice Settings Predict Longer Survival for People With Multiple Myeloma LBA107
A new study analyzing demographic statistics from the National Cancer Database identified multiple socio-economic factors, including private insurance, living in a regionally higher-income area, and receiving treatment in certain practice settings as being associated with longer survival for patients with multiple myeloma. Learn More

Racial Disparities in Access to Timely Cancer Treatment Nearly Eliminated in States With Medicaid Expansion LBA1
Previous racial disparities in timely cancer treatment between African American and white patients practically disappeared in states where Medicaid access was expanded under the Affordable Care Act (ACA), according to a new analysis of electronic health records of over 30,000 patients. Learn More

Adding Enzalutamide to Standard First-Line Treatment Improves Survival for Men With Metastatic Hormone-Sensitive Prostate Cancer LBA2
An interim analysis of the international randomized, phase III ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer (mHSPC) who received the non-steroidal anti-androgen (NSAA) medicine enzalutamide (Xtandi) along with the standard of care treatment were alive after 3 years compared with 72% of men who received other NSAAs along with standard treatment. Learn More

Maintenance Therapy With PARP Inhibitor Olaparib Delays Progression of BRCA-Related Pancreatic Cancer LBA4
The randomized, phase III POLO trial found that maintenance therapy with the PARP inhibitor olaparib (Lynparza) significantly delayed the progression of metastatic pancreatic cancer in patients with BRCA gene mutations compared with placebo (median progression-free survival: 7.4 months vs. 3.8 months, respectively). Learn More

Find more information about the 2019 ASCO Annual Meeting.

Back to Top